High - throughput RNAi screening identifies a role for TNK 1 in growth and survival of 1 pancreatic cancer cells
نویسندگان
چکیده
High-throughput RNAi screening identifies a role for TNK1 in growth and survival of 1 pancreatic cancer cells 2 3 Meredith C. Henderson, Irma M. Gonzales, Shilpi Arora, Ashish Choudhary, Jeffrey M. 4 Trent, Daniel D. Von Hoff, Spyro Mousses, David O. Azorsa 5 6 Clinical Translational Research Division, The Translational Genomics Research Institute, 7 Phoenix, AZ, 85004, USA 8 Pharmaceutical Genomics Division, The Translational Genomics Research Institute, Scottsdale, 9 AZ, 85259, USA 10 Cancer and Cell Biology Division, The Translational Genomics Research Institute, Phoenix, 11 AZ, 85004, USA 12 Genetic Basis of Human Disease Division, The Translational Genomics Research Institute, 13 Phoenix, AZ, 85004, USA 14 15 Correspondence to: 16 David O. Azorsa, Ph.D. 17 Clinical Translational Research Division 18 Translational Genomics Research Institute 19 Scottsdale, Arizona 85259, Phone 602 358-8352 20 [email protected] 21 Running title: TNK1 is a pancreatic cancer oncogene 22
منابع مشابه
High-throughput RNAi screening identifies a role for TNK1 in growth and survival of pancreatic cancer cells.
To identify novel targets in pancreatic cancer cells, we used high-throughput RNAi (HT-RNAi) to select genes that, when silenced, would decrease viability of pancreatic cancer cells. The HT-RNAi screen involved reverse transfecting the pancreatic cancer cell line BxPC3 with a siRNA library targeting 572 kinases. From replicate screens, approximately 32 kinases were designated as hits, of which ...
متن کاملCancer Genes and Genomics High-throughput RNAi Screening Identifies a Role for TNK1 in Growth and Survival of Pancreatic Cancer Cells
To identify novel targets in pancreatic cancer cells, we used high-throughput RNAi (HT-RNAi) to select genes that, when silenced, would decrease viability of pancreatic cancer cells. The HT-RNAi screen involved reverse transfecting the pancreatic cancer cell line BxPC3 with a siRNA library targeting 572 kinases. From replicate screens, approximately 32 kinases were designated as hits, of which ...
متن کاملCancer Therapy: Preclinical Synergistic Effect between Erlotinib and MEK Inhibitors in KRAS Wild-Type Human Pancreatic Cancer Cells
Purpose: The combination of erlotinib and gemcitabine has shown a small but statistically significant survival advantage when compared with gemcitabine alone in patients with advanced pancreatic cancer. However, the overall survival rate with the erlotinib and gemcitabine combination is still low. In this study, we sought to identify gene targets that, when inhibited, would enhance the activity...
متن کاملA screen for inducers of bHLH activity identifies pitavastatin as a regulator of p21, Rb phosphorylation and E2F target gene expression in pancreatic cancer
The average survival for patients with Pancreatic Ductal Adenocarcinoma (PDA) is merely 6 months, underscoring the need for new therapeutic approaches. During PDA progression, pancreatic acinar cells lose activity of the ClassI/II bHLH factors that regulate quiescence. We previously found that promoting transcriptional activity of the Class I bHLH factor E47 in highly aggressive PDA cells induc...
متن کاملSynergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.
PURPOSE The combination of erlotinib and gemcitabine has shown a small but statistically significant survival advantage when compared with gemcitabine alone in patients with advanced pancreatic cancer. However, the overall survival rate with the erlotinib and gemcitabine combination is still low. In this study, we sought to identify gene targets that, when inhibited, would enhance the activity ...
متن کامل